Author: igdadmin

November 16, 2022

Be sure to catch up on the latest happenings in our fall newsletter here!

November 1, 2022

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met…

November 1, 2022

October 2022 Webinar Event View Webinar Here This webinar will cover the cardiac and neurologic manifestations of hereditary amyloidosis, diagnostic…

September 16, 2022

CAMBRIDGE, Mass. and TARRYTOWN, N.Y., Sept. 16, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced positive interim results from an ongoing…

August 24, 2022

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 27, 2021– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the HELIOS-A Phase 3…

July 14, 2022

Read our latest newsletter here.

July 14, 2022

July 2022 Webinar Event View the recorded webinar below View Webinar Here Dr. Zonder will describe recent advances in the…

June 24, 2022

CAMBRIDGE, Mass. and TARRYTOWN, N.Y. (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced additional…

June 23, 2022

Prothena has recently implemented an amendment for the AFFIRM-AL Phase 3 study of birtamimab in Mayo Stage IV AL (light…

June 21, 2022

New Drug Application filing anticipated based on positive data from interim analysis Positive high-level results from the NEURO-TTRansform Phase III…